Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) is a clinical-stage biopharma leader developing non-viral allogeneic cell therapies and genetic medicines. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access verified information about PSTX's CAR-T programs, gene editing innovations, and manufacturing advancements. Our curated collection includes press releases on clinical data readouts, FDA designations, collaboration expansions with partners like Roche, and financial performance updates.
Key content categories cover therapy development progress across oncology and rare diseases, technology platform enhancements, and business development activities. Bookmark this page for timely updates on Poseida's pioneering work in TSCM-rich cell therapies and its growing pipeline of precision genetic medicines.
Poseida Therapeutics (Nasdaq: PSTX) has appointed three new members to its Scientific Advisory Board (SAB), enhancing its expertise in CAR-T cell therapy. The new members are Dr. Luca Gattinoni, Dr. Christine Brown, and Dr. Joseph Melenhorst, who are recognized leaders in immuno-oncology. CEO Eric Ostertag highlighted the significance of these appointments, as the new SAB will contribute to the development of next-generation therapies leveraging Poseida's proprietary genetic engineering technologies. These developments could advance the company's treatment options for cancer patients.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that CEO Eric Ostertag will present at the BofA Securities 2021 Virtual Health Care Conference on May 12, 2021, at 2:45 PM ET. The presentation will focus on the company's proprietary genetic engineering technologies aimed at developing cell and gene therapeutics. A webcast will be available on the Poseida website, with an archived replay accessible for about 30 days post-presentation. Poseida is committed to advancing innovative therapies to address significant medical needs.
On April 27, 2021, Poseida Therapeutics (NASDAQ: PSTX) announced three data presentations at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, set for May 11-14, 2021. The key presentations include an oral presentation on a novel delivery system for transgene expression and two poster presentations focusing on CAR-T therapies targeting multiple myeloma and acute myeloid leukemia. These advancements showcase Poseida's commitment to developing innovative cell and gene therapeutics that may address significant medical challenges.
Poseida Therapeutics (Nasdaq: PSTX) announced participation in two upcoming virtual investor conferences. Eric Ostertag, CEO, will speak at the Raymond James Cell Therapy for Oncology Symposium on April 22, 2021, discussing the manufacturing of off-the-shelf cell-based therapy. Additionally, he will host a Fireside Chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021. Webcasts are available on Poseida's website, with replay options for around 30 days.
Poseida Therapeutics (Nasdaq: PSTX) has appointed Dr. Carl June, a leader in immunotherapy, to chair its Immuno-Oncology Scientific Advisory Board (SAB). This strategic move aims to enhance Poseida's research and development in innovative cell and gene therapies. Dr. June's expertise is expected to significantly influence the company's direction as it advances its autologous and allogeneic CAR-T programs. The SAB will focus on both immuno-oncology and gene therapies, reinforcing Poseida's commitment to overcoming limitations in current therapeutic approaches.
Poseida Therapeutics (PSTX) reported significant advancements in its clinical programs and financial outcomes for 2020, marking a transformative year following its IPO. The company highlighted ongoing trials for P-BCMA-101 and P-PSMA-101, with promising results in treating multiple myeloma and prostate cancer, respectively. R&D expenses rose to $103.5 million, while net losses increased to $129.8 million. However, Poseida ended the year with a strong cash position of $309.2 million, enabling further development of its innovative gene therapies.
Poseida Therapeutics (NASDAQ: PSTX) has showcased significant advancements in its clinical and preclinical pipeline during a virtual R&D Day on February 24, 2021. The event highlighted novel technologies, including CAR-T programs and gene therapy approaches. Key updates included progress on the P-PSMA-101 trial for metastatic prostate cancer and promising data on P-BCMA-101 for multiple myeloma. Additional insights into the Cas-CLOVER gene editing system and future product candidates were shared, underscoring Poseida's commitment to developing innovative therapeutics to address unmet medical needs.
Poseida Therapeutics (NASDAQ: PSTX) announced a virtual R&D Day scheduled for February 24, 2021, from 10:00 am to 2:00 pm ET. The event will include presentations from executive leadership and experts on liver disease and hemophilia gene therapy, focusing on Poseida's cell and gene engineering technologies and CAR-T programs. Attendees can access the live webcast on Poseida's website, with a replay available for 30 days. The company aims to showcase its innovative approaches and new strategies for 2021 and beyond.
Poseida Therapeutics (NASDAQ: PSTX), a clinical-stage biopharmaceutical company, will participate in a pre-recorded presentation during the SternIR Virtual Corporate Access Event from January 11-14, 2021. CEO Eric Ostertag will present, and management will be available for one-on-one investor meetings. The presentation can be viewed on Poseida's website starting January 11, 2021, at 7:00 a.m. ET for 30 days. Poseida focuses on innovative gene engineering technologies aimed at creating advanced cell and gene therapeutics.
Poseida Therapeutics (NASDAQ: PSTX) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 21, 2020. This inclusion is significant as the NBI tracks the performance of biotechnology and pharmaceutical companies meeting specific eligibility requirements. The company is focused on developing innovative cell and gene therapies through its proprietary gene engineering platforms. This milestone could enhance visibility and prestige for Poseida, potentially benefiting its market performance and investor interest.
